<code id='C7C06617A2'></code><style id='C7C06617A2'></style>
      • <acronym id='C7C06617A2'></acronym>
      <center id='C7C06617A2'><center id='C7C06617A2'><tfoot id='C7C06617A2'></tfoot></center><abbr id='C7C06617A2'><dir id='C7C06617A2'><tfoot id='C7C06617A2'></tfoot><noframes id='C7C06617A2'>
      • <optgroup id='C7C06617A2'><strike id='C7C06617A2'><sup id='C7C06617A2'></sup></strike><code id='C7C06617A2'></code></optgroup>
        5. <b id='C7C06617A2'><label id='C7C06617A2'><select id='C7C06617A2'><dt id='C7C06617A2'><span id='C7C06617A2'></span></dt></select></label></b><u id='C7C06617A2'></u>
          <i id='C7C06617A2'><strike id='C7C06617A2'><tt id='C7C06617A2'><pre id='C7C06617A2'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-08-11 13:03:16 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：21
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Flash flooding emergencies prompt evacuations in Kentucky, Tennessee
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles